Scott Lee is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 13 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11370 Anderson St
Loma Linda, CA 923543450
Telephone
909-558-2870Registry record last updated 1 Jul 2008.
Clinical trials
- A Performance Evaluation of the Enlite 3 Sensor
Sponsor: Medtronic MiniMed, Inc.
- In Clinic Evaluation of the PLGM Feature
Sponsor: Medtronic MiniMed, Inc.
- Threshold Suspend in Pediatrics at Home
Sponsor: Medtronic MiniMed, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20251 payment
- Novo Nordisk IncProgram year20252 payments
- Mannkind CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
38.4%GLP-1 receptor agonist12.8%Ozempic89%Mounjaro12%Part D<11 patientsInsulin Analog9.1%Lantus Solostar39%Toujeo Max Solostar17%Humalog11%Insulin Lispro Kwikpen U-10011%Lantus11%Novolog11%Part D<11 patients+ 6 more classes in this area
Cardiovascular
32.4%Statin11.6%Atorvastatin Calcium59%Rosuvastatin Calcium24%Pravastatin Sodium17%Part D<11 patientsAngiotensin receptor blocker (ARB)5.7%Losartan Potassium39%Olmesartan Medoxomil36%Valsartan24%Part D<11 patients+ 8 more classes in this area
Hormonal (systemic)
20.7%l-Thyroxine18.1%Levothyroxine Sodium62%Synthroid38%Part D≥30 patientsl-Triiodothyronine1.5%Liothyronine Sodium100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”